BRAFandTERTpromoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients

作者：Langping Jin, Endong Chen, Siyang Dong, Yefeng Cai, Xiangjian Zhang, Yili Zhou, Ruichao Zeng, Fan Yang, Chuanmeng Pan, Yehuan Liu, Weili Wu, Mingzhao Xing, Xiaohua Zhang, Ouchen Wang · 发表于：Oncotarget · 年份：2016 · DOI：10.18632/oncotarget.7811 · 被引用次数：126 · 研究领域：Thyroid Cancer Diagnosis and Treatment、Cancer-related Molecular Pathways、Lung Cancer Treatments and Mutations

// Langping Jin 1, * , Endong Chen 1, * , Siyang Dong 1 , Yefeng Cai 1 , Xiangjian Zhang 1 , Yili Zhou 1 , Ruichao Zeng 1 , Fan Yang 1 , Chuanmeng Pan 1 , Yehuan Liu 1 , Weili Wu 2 , Mingzhao Xing 3 , Xiaohua Zhang 1 , Ouchen Wang 1 1 Department of Surgical Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China 2 Department of Surgical Oncology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China 3 Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA * These authors have contributed equally to this work Correspondence to: Ouchen Wang, e-mail: oncology099@163.com Xiaohua Zhang, e-mail: Zhangxiaohua925@163.com Keywords: papillary thyroid carcinoma, BRAF V600E mutation, TERT promoter mutation, molecular marker, prognosis Received: October 09, 2015 Accepted: January 29, 2016 Published: March 01, 2016 ABSTRACT The role of telomerase reverse transcriptase (TERT) gene promoter mutations in the aggressiveness of papillary thyroid cancer (PTC) remains to be further investigated. Here we examined the relationship of TERT promoter mutations and BRAF V600E with the clinicopathological features of PTC in 653 patients. Sanger sequencing of genomic DNA from primary PTC tumors was performed for mutation detection and genotype-clinicopathological correlat...